ERBB2 and breast carcinoma: The results of a cell viability assay revealed that antiproliferative activity measured by ATP was more potent in PIK3CA-wt/HER2+ breast cancer cell lines (Fig. 3d, red bars) than in PIK3CA–mut HER2+ breast cancer cell lines (Fig. 3d, blue bars).